FSGS

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Primary FSGS is a leading cause of end stage renal disease (ESRD) in both children and adults, with loss of kidney function in 50% of patients over 10-years. The FSGS Clinical Trial was sponsored by the NIH in response to this poor prognosis and the need for rigorously tested treatment modalities. The FSGS Clinical Trial is a Phase III randomized trial of children and young adults age 2 to 40 years being conducted at over 100 sites in North America. Eligibility criteria include biopsy-confirmed primary FSGS, corticosteroid resistance (Up/c ratio < 1.0 during min 4 wks prednisone therapy with cumulative minimal dose of 56 mg/kg prednisone or equivalent), persistent proteinuria (Up/c ratio > 1.0), and an estimated GFR ? 40 ml/min/1.73m2.